时间：2月22日星期三16:00-17:30

Time：4:00-5:30 PM，Wednesday, Feb. 22nd，2023

主持人：西湖大学生命科学学院特聘研究员 周挺

    Host：Dr. Ting Zhou, PI of School of Life Sciences

    地点：云谷校区E10-201（线下）；应急医学中心1号楼学术报告厅（线上）

    Venue：E10-201，Yungu Campus (onsite)

            Lecture Hall, Building 1, CIDR (online)

主讲嘉宾/Speaker:

Jun Wang, Assistant Professor, Department of Pathology, New York University Grossman School of Medicine/ Laura and Isaac Perlmutter Cancer Center, New York University Langone Health

Dr. Jun Wang is currently an Assistant Professor of Pathology at NYU Grossman School of Medicine. He got his PhD in Chinese Academy of Sciences, and Postdoc training at Yale by Dr. Lieping Chen.  Dr. Wang possesses over eighteen years of expertise in cancer immunology with a focus on the discovery of novel immune checkpoints and how to utilize these molecular pathways for cancer immunotherapy. Other than his early experience in the liver toxicity mechanisms of anti-4-1BB immunotherapy, he built cutting-edge genome-scale receptor and function array technologies to characterize FGL1/LAG-3, Siglec-15 etc. as promising cancer immunotherapy targets. These works informed the development of anti-LAG-3 Relatilmab recently approved by FDA for melanoma, and led to the clinical development of anti-Siglec-15 in human cancers. Dr. Wang’s experiences in immunotherapy also have been recently applied to understand COVID-19 immunopathogenesis and the development of novel COVID-19 immunotherapies that targets virus-immune interactions. His lab is committed to discover key immune checkpoints in the human diseases environments, to deep understand their molecular & diseases biology, and design cutting-edge immunotherapies based on these novel mechanisms for treating human cancer and autoimmunity.

讲座摘要/Abstract:

Although the success of immune-checkpoint blockade has revolutionized cancer treatment, a number of tumors do not respond or develop resistance, especially in immunologically cold tumors. A potential mode of resistance is immune evasion of T-cell immunity involving myeloid-related dysregulation. To map such mechanisms of resistance we developed functional screening strategies to identify key regulators for antigen presentation (AP) as well as innate sensing. We built a comprehensive regulatory network for MHC-I modulation and defined a membrane-associated AP inhibitory axis as broadly applicable therapeutic targets for both leukemia and solid cancers. Our findings will facilitate our understanding in the tumor immune evasion mechanisms and foster the development of future antigen presentation inhibitor-guided immunotherapies for cancer and beyond.

联系人/Contact：

生命科学学院

于文越 yuwenyue@westlake.edu.cn